Slow progress is better than no progress and while the U.S. government is moving at a snail’s pace when it comes to cannabis legalization, there has been recent movement on the issue.
Last week, the Food and Drug Administration announced that it has concluded that a “new regulatory pathway” is necessary for cannabidiol-infused products as the current rules governing food and drink are insufficient.
The regulatory agency also denied three citizen petitions requesting that the FDA allow the marketing of CBD products as dietary supplements.
“The FDA’s existing foods and dietary supplement authorities provide only limited tools for managing many of the risks associated with CBD products,” said Janet Woodcock, principal deputy commissioner for the FDA.
“Given the available evidence, it is not apparent how CBD products could meet safety standards for dietary supplements or food additives.”
The agency says they don’t have enough evidence to determine how much CBD can be consumed, and for how long, before causing harm.
“The FDA looks forward to working with Congress to develop a cross-agency strategy for the regulation of these products to protect the public’s health and safety,” it said.
Other Cannabis Regulatory Hurdles
Last year, President Joe Biden instructed the Department of Health and Human services and the Attorney General to review the Schedule 1 classification of marijuana under the Controlled Substances Act (the same level as heroin).
“Yeah, and let me just…